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Background/aim: COVID - 19 disease may be seen with different clinical presentations in pregnant women. Comorbid diseases are
important factors affecting the progression of this disease. In this study, we aimed to evaluate the clinical and laboratory findings in
pregnant women with COVID - 19 who had no comorbid disease.
Material and methods: This retrospective designed study included 217 patients with Covid PCR positive in typically COVID - 19 clinic.
The patients were classified into asymptomatic, nonsevere, and severe disease groups. The symptoms, laboratory results, hospital followups and intensive care records of the patients and the findings of new borns are presented.
Results: Most of the patients (78%) were in the third trimester of pregnancy, and 103 patients in the study group had severe disease.
Fever in the non-severe group and respiratory distress in the severe group were the most common symptoms in the patients. The severe
clinical manifestations were specifically observed in the third trimester patients. In the severe group, neutrophil, lactat dehydrogenase,
ferritin, CK - MB, IL – 6, and hospital stay were statistically higher than those in other groups (p < 0.05). Increase in BUN and creatine
were the most predictive parameters in intensive care admission. While the intensive care unit (ICU) requirement was higher in patients
in the severe group, premature birth was observed more frequently in the severe group (p < 0.05).
Conclusion: COVID - 19 positive pregnant women were mostly detected in the third trimester, and the disease was more severe in this
period. Also, the need for intensive care, the rate of delivery by caesarean section, and the rate of preterm delivery of these pregnant
women were also found to be high.
Key words: COVID-19, pregnancy, ferritin, severe disease, 3rd trimester

1. Introduction
COVID - 19, a disease caused by SARS-CoV-2, is highly
infectious and induces death globally. Based on early
reports in pregnant women, the clinical course of COVID
- 19 is typically mild (86%), severe (9%) or critical (5%),
which is like the clinical course distribution seen in the
non-pregnant population [1].
SARS - CoV - 2 infections seem to cause serious
pulmonary manifestations, including pneumonia [2], acute
respiratory distress syndrome, pervasive microemboli,
and coagulation perturbations [3]. Therefore, an increase
in morbidity and mortality among pregnant women
is a reasonable concern. Physiological changes such as

hypercoagulation, alterations in cell - mediated immunity
[4], decreased lung capacity and pulmonary secretion
clearance [5] may increase both the susceptibility and
clinical severity of pneumonia in pregnant women. However,
common symptoms in pregnancy, such as physiological
dyspnea, may delay a diagnosis when pathologic dyspnoea
secondary to COVID - 19 is not distinguished [6]. Comorbid
diseases, such as diabetes, hypertension, arrhythmia,
gestational diabetes and hypertension and preeclampsia,
increase morbidity and mortality. However, it could not
be differentiated whether the current situation was due to
the clinical course of COVID - 19 disease or the underlying
comorbid condition [7].
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This study aims to examine the clinical course caused
by this viral infection, laboratory findings, the need for
intensive care, morbidity and mortality rates in COVID 19 positive pregnant women without comorbid conditions
according to the severity of the disease. We also aim
to reveal the possible differences between clinical and
laboratory findings that occur according to the severity of
the disease.
2. Materials and methods
This retrospective study included pregnant women who
were diagnosed with COVID -19 in a tertiary medical
centre between 1 March and 30 November 2020. The study
was approved by the Local Ethics Committee (No: 594).
In our clinic, PCR test and thorax computed tomography
were evaluated when the pregnant women were admitted
to us with fever, flu - like symptoms (headache, pain and
burning sensation in the throat and eyes, nasal congestion,
muscle and joint pain), respiratory symptoms (cough,
shortness of breath and chest pain), gastrointestinal
symptoms (nausea-vomiting and diarrhoea) and loss of
smell and / or taste. In addition, the COVID - 19 PCR
test was performed on patients with a history of contact
with a COVID - 19 positive patient, or who were interned
for obstetric reasons. Patients with two positive COVID
- 19 PCR tests at 24–48 h intervals or patients with a
negative COVID-19 PCR test but with typical COVID - 19
compatible thoracic computed tomography (CT) findings
were considered COVID - 19 positive and included in the
study. Pregnant women with comorbid diseases, such as
obesity, diabetes, hypertension, arrhythmia, gestational
diabetes and hypertension, gestational cholestasis,
preeclampsia, atypical HELLP and chronic liver disease,
were excluded from the study (Figure).
In this study, clinical and laboratory findings at
the time of admission to the hospital and clinical and
laboratory findings at the time of admission to the
intensive care unit (ICU) in patients who needed to be
followed up in the ICU were recorded as data. The patients’
time interval between symptom onset and admission, vital
signs, oxygen saturation, gestational age, gestational week,
delivery mode, COVID - 19 -related symptoms with white
blood cell (WBC) count, D - Dimer, liver and kidney
function markers, cardiac panel (CK-MB, Troponin - I),
inflammatory parameters and thorax CT findings were
recorded. Clinical and laboratory findings were evaluated
separately at the hospitalisation of the ICU. In addition, two
consecutive COVID - 19 PCR test results obtained from
newborns at the time of delivery and within 24 – 48 hours,
alongside the fifth minute APGAR score and birth weight
records, were examined. The thorax CTs of the patients
were evaluated by two experienced radiologists, and they
were classified into 4 grades: early, progression, pike and
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resolution [8]. According to the classification made by
the World Health Organisation (WHO), according to
clinical findings and thorax CT results, the disease of the
patient was grouped as mild, moderate, severe and critical
stages [9]. Mild and moderate patients were regrouped
as nonsevere. Since critically ill patients were followed
in the ICU at the time of admission, these patients were
excluded in the study. In addition to these groups, patients
with COVID - 19 without any symptoms were included in
the asymptomatic group. Thus, three groups were formed
for the study: asymptomatic, nonsevere, and severe.
The clinical and laboratory findings of the patients were
compared according to the classifications made. Also, the
clinical and laboratory findings of the patients taken to
the ICU and those requiring no intensive care were also
compared.
2.1. Statistical analysis
Statistical analysis was performed using SPSS version 22
(IBM, Armonk, NY, USA). The normality of distribution
was analysed using Kolmogorov – Smirnov test. Categorical
data were expressed as numbers and percentages, and
the chi-square test was used for comparison. The Mann
– Whitney U test was used for comparison between two
independent groups, while the comparison for more than
two independent groups was made with the Kruskal –
Wallis test. If statistically significant results were observed
in the Kruskal – Wallis test, the Mann – Whitney U test
was performed between the groups for post-hoc analysis.
The values less than 0.05 were considered statistically
significant.
3. Results
The data of 217 out of 293 COVID - 19 positive patients
meeting the criteria were examined; 55 (25.3%) of the
patients were in the asymptomatic group, 59 (27.2%) in
the nonsevere group and 103 (47.5%) in the severe group
(Table 1). Also, 7.4% of the patients were in the first
trimester, 13.8% in the second trimester, and 78.8% in the
third trimester (Table 1).
There were statistically significant differences
when the clinical symptoms and chest CT findings of
symptomatic patients were compared. The duration of
symptom presence was longer before admission to the
hospital in the severe group, and the rate of admission
with respiratory tract and GIS symptoms and signs was
higher, while the rate of presentation with fever, flu - like
symptoms and loss of taste sensation was higher in the
nonsevere group (p < 0.05) (Table 1). Radiologically, only
two of the involvements were unilateral, while the others
were bilateral. Consistent with clinical staging, the rate
of the most frequent progression stage was higher in the
severe group, while the rate of early stage was higher in the
nonsevere group (Table 1).
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Fever
Flu-like Symptom
Respiratory Symptom
Gastrointestinal
symptom

History of
contact with
COVID-19
positive
individual

Loss of Taste and Smell

Hospital
admission due to
obstetric reason

PCR and/or Thorax CT

COVID-19 positive
Diabetes mellitus
Hypertension
Arrhythmia
Asthma
Obesity
Chronical liver disease
Gestational diabetes
Gestational cholestasis
Preeclempsia
HEELP

Exclusion
criteria

Yes

No

Inclusion in
the study

Refer to
other center
Figure. Inclusion and exclusion criterias of the Covid-19 positive pregnant women.

During hospitalisation, 94/217 (43.3%) of births
occurred, and 55/94 (58.5%) of them were caesarean
section, 39/94 (41.5%) were vaginally, and 39.4% of them
were preterm. Although the rate of caesarean delivery
in the severe group exceeded those of the other two
groups, there was no statistically significant difference
(p > 0.05). The rate of preterm labour was higher in the
severe group compared to the other two groups, and there
was a statistically significant difference (p < 0.05). While
maternal hypoxemia and fetal distress constituted the
caesarean indication in the severe group, the difference was

statistically significant in the other two groups (p < 0.05)
(Table 2). In the COVID -19 PCR scans of 92 newborns, the
first COVID - 19 RT – PCR test taken immediately one baby
was born was positive (the APGAR score was 9, and the girl
was 3450 gr.). Significant differences were found between
the groups regarding length of hospital stay, aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
D - DIMER, C -reactive protein (CRP), neutrophil (NEU),
lactate dehydrogenase (LDH), ferritin, creatine kinase MB
(CK - MB), interleukin - 6 (IL - 6), lymphocyte, eosinophil
and albumin levels (p < 0.05) (Table 3).
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Table 1. Clinical characteristics of COVID-19 positive pregnant women according to clinical classification on hospital admission.
Asymptomatic Median
(min-max)/ n (%) (n:55)

Non-severe Median
Severe Median
(min-max)/ n (%) (n:59) (min-max)/ n (%) (n:103)

p value

Age (years)

28 (17-45)

30 (16–41)

30 (18–44)

0.758

Symptom onset-admission to the
hospital day

-

7 (2–14)

8 (3–18)

0.006

Trimestr

0.108

1

4 (7.3%)

7 (11.9%)

5 (4.9%)

2

3 (5.5%)

8 (13.6%)

19 (18.4%)

3

48 (87.3%)

44 (74.5%)

70 (67.9%)

Fever ( ≥ 38.3 ºC)

-

31 (52.5% )

11 (10.7%)

<0.001

Flu-like symptoms

-

33 (55.9%)

4 (3.9%)

<0.001

Respiratory Symptoms

-

30 (50.8%)

99 (96.1%)

<0.001

Loss of taste and smell

-

22 (37.3%)

12 (11.7%)

<0.001

GIS Symptoms

-

7 (11.9%)

22 (21.4%)

<0.001

COVID-19-related symptoms

Chest CT staging

<0.001

Early

-

44 (74.6%)

6 (5.8 %)

<0.001

Progression

-

8 (13.6%)

90 (87.4%)

<0.001

Peak

-

0

7 (6.8%)

No involvement

-

7 (11.9%)

-

Note: GIS: Gastrointestinal system; CT: Computed Tomography.
Table 2. Delivery characteristics of COVID-19 positive pregnant women according to clinical classification.
Asymptomatic Median
(min-max)/ n (%) (n:55)

Non-severe Median
(min-max)/ n(%) (n:59)

Severe Median
(min-max)/ n (%) (n:103)

p value

C/S

17 (50%)

8 (44.4%)

30 (71.4%)

0.068

Vaginal

17 (50%)

10 (55.6%)

12 (28.6)

Preterm birth

4 (11.8%)

6 (33.3%)

27 (64.3%)

<0.001

Previous C/S

13 (76.5%)

5 (62.5%)

3 (10%)

<0.001

Fetal distress

1 (2.9%)

-

12 (28.6%)

<0.001

Maternal hypoxia

-

-

9 (21.4%)

Induction failure

2 (5.9%)

-

4 (9.5%)

Malposition

1 (2.9%)

3 (16.7%)

2 (4.8%)

Baby Birth Weight (gr)

3450
(2780–3200)

3240
(1700–4300)

3120
(1650–3200)

0.308

5. min APGAR

9 (6–10)

9 (7–10)

8 (3–9)

0.674

Hospital days

3 (1–5)

5 (3–9)

8 (6–16)

<0.001

Delivery mode

Other C/S indications

Note: C/S: Cesarean section; APGAR: Appearance, Pulse, Grimace, Activity, and Respiration.
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Tablo 3. Laboratory findings of COVID-19 positive pregnant women according to clinical classification on hospital admission.
Asymptomatic (n:55)
Median (min-max)/ n (%)

Non-severe (n:59)
Median (min-max)/ n (%)

Severe (103)
Median (min-max)/ n (%)

p value

Heart rate (n/min)

110 (90–145)

110 (91–146)

112 (90–150)

0.223

Systolic pressure (mm/Hg)

80 (60–98)

81 (62– 99)

87 (64– 100)

0.313

Diastolic pressure (mm/Hg)

90 (77–122)

90 (78–142)

91 (79–142)

0.871

21 (14–23)

β

22 (15–34) γ

33 (19–54)

< 0.001

SPO2

97 (95–99)

β

96 (90– 98) γ

90 (75– 91)

< 0.001

WBC (109/L)

9.2 (3.5–15.4) αβ

7.6 (2.2–18.6) γ

6.4(2.2–14.5)

0.027

10.2 (2–26.4) γ

7.8(1.1–25.5)

0.013

80 (62–94) γ

88 (61–99)

< 0.001

Respiratory rate (n/min)

Lymphocytes (%)

17.1(3.9–31.5)

Neutrophils (%)

74.5 (65–94) αβ

αβ

Eosinophils %)

3.4 (0.1–4.8)

3.3 (0– 4.4) γ

0.6 (0–3.2)

< 0.001

PLT (109 / L)

252 (102–340)

223 (51–355)

218 (42–367)

0.922

BUN (mg/dL)

29 (10– 317)

23 (9 – 238)

26 (8–331)

0.284

Creatinine (mg/dL)

0.63 (0.3– 1.6)

0.7(0.3– 1.67)

0.7(0.3–1.74)

0.310

AST (U/L)

36 (14–228)

35 (16– 242) γ

37 (36– 1265)

0.010

ALT (U/L)

19 (8–130) β

18 (8– 133) γ

38 (27–1152)

0.031

269 (127– 726) γ

330 (138– 2271)

<0.001

64(12 –292)

70 (13– 658)

0.070

30 (28– 49)

29 (17– 45)

< 0.001

352(120–1230) γ

527(145–5948)

0.004

47 ( 9–578) γ

227 ( 12– 762)

< 0.001

27.8 (11 – 145) γ

72 (15 –271)

< 0.001

1.32 (0.55–6) γ

3 (0.56 –7.8)

< 0.001

0.1 (0.1– 0.6)

0.1 (0.1–0.63)

0.009

16 (4.2–101)

56 (5–112)

< 0.001

β

LDH (U/L)

183 (126–422)

CK (U/L)

34 (13–296)

ALB (g/L)

40 (30–51)

αβ

αβ

D-Dimer (ng/mL)

240(119–1278)

Ferritin (ng/mL)

26 ( 7–270)

αβ

αβ

CRP (mg/L)

6 (2 – 27)

CK-MB (ng/mL)

0.77 (0.39–8.8) αβ

Troponin- I (ng/mL)

0.1 (0.1–0.4)

IL- 6 (ng/L)

7 (4–72)

β

Note: SPO2: oxygen saturation; WBC: white blood cell count; PLT: platelet count; BUN: blood ure-nitrogen; ALT: alanine aminotransferase,
AST: aspartate aminotransferase; LDH: lactate dehydrogenase; CK: creatine kinase; ALB: albümin; CRP: C-reactive protein; CK-MB:
creatine kinase MB, IL-6: Interleukin-6. α: significant difference between asymptomatic and non-severe group; β: significant difference
between asymptomatic and severe group; γ: significant difference between non-severe and severe group.

During hospitalisation, 37 patients (4 asymptomatic, 7
non - severe and 26 severe groups) were followed up in the
ICU for approximately 4 days (2 – 6) due to worsening in
breathing; 33 out of 37 patients (89.2%) entering the ICU
were 3rd trimester patients (Table 4). Thorax CT of eighteen
patients taken during admission to intensive care were
compatible with progression and 19 with peak stage. Twenty
of the patients were given high flow oxygen (HFO), and
17 of them were taken to mechanical ventilation support,
three of which were invasive. During the hospital follow-up
period, 10 / 37 (27%) of the patients followed in the ICU
did not give birth, while 73% (17 caesarean and 10 vaginal
deliveries) were delivered. A total of 22.2% of those who
gave birth (6 / 27) were taken to the prenatal care unit, and
21 / 27 (77.8%) were taken to the postnatal intensive care
unit. Duration of symptoms before hospitalisation, body

temperature, systolic blood pressure, pulse, respiratory rate,
neutrophil percentage, blood ure-nitrogen (BUN), creatine
(CREA), AST, ALT, LDH, CK, D - Dimer, Ferritin, CRP,
CK - MB, Tro I and IL - 6 median were high; the 5 - min
APGAR score, SPO2, WBC, lymphocyte and eosinophil
percentage and ALB median were low, and the difference
was statistically significant (p < 0.05) (Tables 4 and 5).
In total, four of our patients who were admitted to ICU
were complicated with postpartum pulmonary embolism
and one patient with prenatal myocarditis. There was
no maternal mortality during hospital follow-up and
treatment.
4. Discussion
In this study, COVID - 19 RT - PCR test positivity was
92.6%, and 47.5% of pregnant women were included in
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Table 4. Clinical characteristics of COVID-19 positive pregnant women according to intensive care unit admission.
Non-ICU (n:180)
Median (min-max)/ n (%)

ICU (n:37)
Median (min-max)/ n (%)

P Value

Age (years)

29 (16–45)

30 (20–42)

0.355

Symptom onset-admission to the hospital day

7 (1– 17)

11 (7–18)

< 0.001

Clinical Stage

0.008

Asymptomatic

51 (28.3%)

4 (10.8%)

Non-severe

52 (28.9%)

7 (18.9%)

Severe

77 (42.8%)

26 (70.3%)

1

15 (8.3%)

1 (2.7%)

2

27 (15.0%)

3 (8.1%)

3

138 (76.7%)

33 (89.2%)

No

113 (62.8%)

10 (27.0%)

Yes

67 (37.2%)

27 (73.0%)

Trimestr

0.225

Delivery

< 0.001

Delivery mode

< 0.001

C/S

38 (21.1%)

17 (45.9%)

Vaginal

29 (16.1%)

10 (27.0%)

C/S indications

< 0.001

Previous C/S

17 (9.4%)

4 (10.8%)

Induction failure

5 (2.8%)

1 (2.7 %)

Malposition

4 (2.2%)

2 (5.4 %)

Maternal hypoxia

4 (2.2%)

5 (13.5%)

Fetal distress

8 (4.4%)

5 (13.5%)

PretermLabor

12 (32.4%)
3120
(1900 –3750)
7 (3–10)

0.006

5. min APGAR

25 (13.9%)
3420
(1650–3200)
9 (6–10)

Hospital stay (day)

5 (1–10)

9 (3–16)

< 0.001

BabyBirthWeight (gr)

0.084
< 0.001

Note: ICU: Intensive-care unit; C/S: Cesarean section; APGAR: Appearance, Pulse, Grimace, Activity, and Respiration.

the severe group. This study is imperative because it is a
comprehensive study conducted in a single centre, including
patients with similar demographic characteristics.
Jie Yan et al. [10] identified fever in 50.9%, cough in
28.4%, and dyspnoea in 7.8% of a group of pregnant
women, and only 6.9% of them were severe. Delahoy et al.
[11] analysed the surveillance data of 598 pregnant women
and identified fever in 59.6% and coughing in 59.2%.
Mohr Sasson et al. [12] reported that 54.5% of 11 pregnant
women showed respiratory symptoms, 27% had fever, and
respiratory symptoms were more common than fever.
However, in the above studies, admission symptoms were
not evaluated following clinical classification. Furthermore,
Pierce-Williams et al. [7] reported application clinical
symptoms of 44 severe and 20 critical pregnant women
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and reported an average of 7 days between the onset of the
symptoms and hospital application.
Typical symptoms of COVID - 19 are fever and
respiratory symptoms, while atypical symptoms include
GIS (abdominal pain, diarrhoea and nausea-vomiting) and
symptoms and signs of neurological involvement [13]. This
was an important determination regarding the fact that
fever, which is the typical symptom of COVID-19 during
the pandemic period, was not in pregnant admissions,
indicating that the clinic could be severe. The absence
of fever in pregnant women in the severe group can be
explained by the increase in immune suppression and
decrease in fever response in parallel with the increase in
the severity of the disease in pregnant women who are
immunosuppressive [4,5].
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Table 5. Laboratory findings of COVID-19 positive pregnant women in ICU admission
Non- ICU Group (n:180)
Median (min-max)/ n(%)

ICU group (n:37)
Median (min-max)/ n(%)

P

Temperature (°C)

37 (36.5 – 39.3)

37.3 (36.5–39)

0.021

Heart rate (n/min)

90 (77–134)

119 (81–145)

0.004

Systolic pressure (mm/Hg)

110 (90–140)

120 ( 98–150)

0.048

Diastolic pressure (mm/Hg)

80 (60–100)

89 (63–109)

0.051

Respiratory rate (n/min)

20 ( 14–34)

26 ( 24–54)

0.012

SPO2

95 ( 80–98)

90 ( 75–95)

< 0.001

WBC

7.6 ( 2.2– 8.6)

7.3 ( 2.3–18.2)

0.003

Lymphocytes

10.8 ( 3.4–31.5)

8.6 ( 1.1–18.6)

0.030

Neutrophils

82 ( 61–96)

85 ( 63 – 99)

0.016

Eosinophils

1.7 ( 0–4.8)

0.6 (0–4.3)

0.004

PLT

233 (51–369)

223 (43–337)

0.875

BUN

23 (8–119)

223 (15–331)

< 0.001

CREA

0.6 (0.3–1.3)

1.45 (0.34–1.74)

< 0.001

AST

35 (14–290)

38 (24–1264)

< 0.001

ALT

19 ( 8–266)

23 (15–1138)

0.003

LDH

257 ( 126–2224)

321 (134–2265)

0.010

CK

56 (11–478)

83 (13–647)

0.021

ALB

33 ( 25–49)

29 (17–40)

< 0.001

D–Dimer

354 (119–3352)

658 (147–5948)

< 0.001

Ferritin

68 (9–634)

293 (7–762)

< 0.001

CRP

31.5 (2–236)

77 (24–271)

< 0.001

CK–MB

0.99 (0.4–8.8)

2 (0.55–8.89 )

< 0.001

Tro I

0.1 ( 0.1–0.4)

0.1 (0.1–0.6)

< 0.001

IL 6

16.2 (4–101)

34 (6.2–105)

< 0.001

Note: ICU: Intensive care Unit, SPO2: oxygen saturation; WBC: white blood cell count; PLT: platelet count; BUN: blood
ure–nitrogen; ALT: alanine aminotransferase, AST: aspartate aminotransferase; LDH: lactate dehydrogenase; CK:
creatine kinase; ALB: albümin; CRP: C–reactive protein; CK-MB: creatine kinase MB, IL-6: Interleukin-6.

In a multicenter study that included 355 COVID - 19
patients, 39.7% of patients were taken to the ICU. It was
emphasised that dyspnoea, tachypnoea and low peripheral
oxygen saturation are important parameters in showing
the severity of the disease, and they might be an indicator
to predict intensive care requirement [14]. A single - centre
study revealed that data such as heart rate, respiratory
rate, and mean arterial pressure did not differ in patients
admitted to the ICU, and the patient required no intensive
care [15].
In a systematic review and meta - analysis of 4062
COVID - 19 positive non-pregnant adult cases, it was
reported that tachypnoea induced by the decrease in
oxygen saturation in critical patients was a discriminative
finding; heart rate did not differ between the severe
and non - severe groups [16,17], and blood pressure

was reported higher in the severe group in a study [16],
while it was not in another study [17]. In our study, like
non - pregnant adults, in pregnant women, there were
no significant differences in blood pressure and heart
rate during application among groups, but the increased
respiratory rate and low oxygen saturation in the severe
group at presentation were found to be statistically
significant compared to the other two groups [14,17]. In
our study, we observed that heart rate and blood pressure
were similar between the groups, but respiratory rate and
oxygen saturation were significantly altered according
to the severity of the disease. Increased respiratory rate
and low oxygen saturation can be important indicators
to distinguish physiological dyspnoea seen in pregnant
women, especially in the third trimester, and dyspnoea
seen in COVID - 19 positive pregnant women.
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Yuming et al. [18] reported that the main laboratory
findings were lymphopenia and elevated CRP in 146
pregnant women, 5.5% of which were severe. In their
research, Scott et al. [19] studied 69 COVID - 19 positive
pregnant women, 15 of which required respiratory support,
and they reported that the lymphocyte rate was lower in
those who required respiratory support; however, WBC,
neutrophil and PLT rates were similar. CRP was elevated
in 63 patients during hospitalisation; however, there was
no statistically significant difference between the groups.
Andrikopoulou et al. [20] reported significantly elevated
ferritin and leucopenia levels in moderate or severe disease
groups, while the differences between ALT, AST, LDH, IL
- 6, CREA, platelets, lymphocyte and D -dimer levels were
reported not statistically insignificant.
In our study, hematological tests of asymptomatic,
non-severe and severe group patients were compared
concurrently. On admission to the hospital, increased
LDH, CRP and IL - 6 and low albumin were found to be
predictive parameters in distinguishing the asymptomatic
group from the non-severe group. However, the most
distinctive predictive parameter among all three groups
was ferritin, and it was found to be the only statistically
significant parameter with an increase above the reference
range in the severe group. When those taken to the ICU
were compared with those who were not, worsening
of breathing in those who were taken to the ICU was
accompanied by increased heart rate, systolic blood
pressure, respiratory rate and decreased oxygen saturation
as parameters show a statistically significant difference.
It was found statistically significant that the median of
lymphocyte and albumin was lower, and NEU, LDH, CRP,
D - DIMER and IL - 6 were higher in those who were taken
to the ICU but were outside the reference range in both
groups. However, ferritin, BUN and CREA, which showed
a statistically significant increase above the reference range
in the intensive care patients, were found to be predictive
parameters. These were important parameters in showing
an increase in inflammation and kidney involvement of
COVID - 19 in those taken to the ICU.
In a multicenter study in France, 617 COVID - 19
infected pregnant women classified as 79.2% non-severe,
15.2% receiving respiratory support (receiving nasal
oxygen and/or mechanical ventilation support) and 5.6%
critical group (receiving invasive mechanical ventilation
or ECMO) were examined. The severity of the disease was
found to be associated with the presence of over 35 years
of age and comorbid conditions. In the neonatal nasal
COVID - 19 RT - PCR test screening, only two newborns
had the test positive. While there was no COVID - 19 related neonatal death, a mother who was followed in the
ICU in the critical form group was lost due to COVID - 19
[21]. Only one patient was found positive in the neonatal
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nasopharyngeal COVID - 19 RT - PCR scan in our study.
This newborn was discharged with recovery with his
mother. We lacked enough cases about the transition from
mother to baby, but in three different studies presented
on this subject, it was stated that the vertical transmission
was not at a significant level [22,23]. In the large - series
prospective multicenter study in the UK, 427 symptomatic
- hospitalised COVID - 19 - infected pregnant women,
81% of whom were in the third trimester, were analysed. A
total of 41% of the patients were aged 35 or over, and 46%
had comorbid conditions [24].
Contrary to the studies mentioned, the majority of
the patients in our study population comprised pregnant
women with severe disease, and 78.8% of the cases were
third trimester pregnancies according to the trimester
distinction. The disease progressed more severely in three
trimesters of pregnant women in our study population.
76.7% of the hospitalised patients and 70.2% of those
taken to the ICU were severe group, 3rd trimester pregnant
women. The reason for the severe course of the disease
in pregnant women infected with COVID - 19 can be
explained by the physiological changes that occur in the
respiratory and immune systems of pregnant women. In
the physiological changes that occur in the immune system
in pregnant women of third trimesters, Th1 and Th2 cell
balance shifts to the Th1 side, and the inflammatory process
dominates. This contributes to exaggerated inflammation
in the pathophysiology of COVID - 19, inducing a cytokine
storm in 3rd trimester pregnant women. In addition, the
increased uterine volume in third trimester pregnancies
elevates the maternal diaphragm, resulting in a severe
course of pneumonia clinic by increasing the sensitivity
of respiratory viruses and decreasing the tolerability
to hypoxia by increasing the physiological changes in
the respiratory system, including the decrease in total
respiratory capacity, functional residual capacity, end expiratory volume and residual volumes of the lung [25].
Following the current literature, 58.5% of the deliveries
in the hospital occurred with caesarean section and 39%
with preterm labour [21,24]. Maternal hypoxemia and
foetal distress constituted 40% of cesarean indication.
Similarly, the rates of caesarean section due to caesarean
section, preterm labour and maternal hypoxemia or
foetal distress were found to be higher, with a statistically
significant difference in pregnant women in the severe
group and those taken to the ICU. In addition, the APGAR
score of the babies of mothers taken to the ICU was found
to be statistically significantly lower, attributed to the
mother’s illness. However, there was no mother or baby
loss because the patient population comprised young and
pregnant women without comorbid conditions, with the
treatment and follow - up protocol of the patients being
conducted by a multidisciplinary team (infectious diseases,
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gynaecology, anaesthesia and perinatology physicians) in
a single centre.
Our study has some limitations. Despite our highpatient admission rates, the records for the data of
outpatients and third trimester pregnant women who
gave birth in our hospital after discharge were excluded
from the study because they could not complete the study
criteria. In addition, this evaluation could not be made
because records for APACHE and Glaskow Coma Scale
were insufficient for patients followed in the ICU. Neonatal
vertical transition was evaluated only by nasopharyngeal
and/or oropharyngeal sampling. The COVID - 19 PCR
study was not performed on respiratory secretions,
cord blood, amniotic fluid, vaginal fluid or breast milk
samples. However, no sampling was done for postpartum
horizontal transition. However, we think that this study is
useful regarding monitoring many cases in a single centre.
5. Conclusion
In this study, it was determined that COVID - 19 diseases
had a more severe course in third trimester pregnant
women, and the period between the onset of COVID – 19
-related symptoms and admission to the hospital was long
in pregnant women with severe disease. Hence, pregnant
women with symptoms in the third trimester should be
followed up closely. Contrary to nonpregnant adults,
observably, fever is not the main symptom in pregnant
women who are physiologically immunosuppressive and
present with respiratory symptoms in pregnant women
with a severe course of the disease. It was found that
dyspnoea is an important symptom in adult patients with a

severe course of the disease, but it can be confused with the
presence of physiological dyspnoea in pregnant women,
and the presence of oxygen saturation and tachypnoea
are important parameters in predicting the severity of
the disease in pregnant women. The most predictive
parameter in showing the disease severity at presentation
was the increase in ferritin in pregnant women. The
most predictive parameters were the increase in BUN
and CREA, in addition to the increase in ferritin in the
intensive care entry. The absence of maternal and neonatal
loss may be related to the follow-up of many patients in a
single centre.
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